Video

Dr. Logan Discusses Ibrutinib Plus Venetoclax in CLL

Author(s):

Aaron Logan, MD, PhD

In Partnership With:

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in chronic lymphocytic leukemia.

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

Results from the TAP CLARITY study showed that the ibrutinib plus venetoclax elicited a complete response (CR) or CR with incomplete hematologic recovery (CRi) rate of 47% for patients with relapsed/refractory CLL. Patients in the relapsed/refractory cohort achieved minimal residual disease (MRD) negativity after 1 year of combination targeted therapy.

Although the numbers are small, it looks like there are good responses, with all patients eventually developing MRD negativity with the combination of Bruton's tyrosine kinase (BTK) inhibition and BCL-2 inhibition. Logan says that he is not sure this combination will achieve immediate approval because it is not yet clear if the FDA is ready to use MRD as an endpoint for clinical trials.

Related Videos
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Related Content
NX-5948 for R/R CLL/SLL | Image Credit: © Dr_Microbe - stock.adobe.com
November 21st 2024

EMA Grants PRIME Designation to NX-5948 for R/R CLL/SLL

Jennie W. Taylor, MD, MPH, associate professor, clinical neurology, University of California, San Francisco, community engagement liaison, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
October 10th 2024

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

FDA
November 20th 2024

FDA Approves New Drug Labeling for Fludarabine Phosphate in CLL

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

First-Line Zanubrutinib in CLL/SLL
November 13th 2024

First-Line Zanubrutinib Prolongs PFS in Real-World Study of Chinese Patients With CLL/SLL

The University of California San Francisco
November 11th 2024

UC Regents Approve UCSF Proton Therapy Center for Cancer Care